Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06179446 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 157
- Enrollment target
NCT06179446 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 157 participants.
The verdict
NCT06179446, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 157 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine. This study is seeking for participants who are: * between the ages of 18 to 49 years old or 65 to 84 years old. * willing and able to follow with all scheduled visits, treatment plan, laboratory tests, lifestyle changes, and other study procedures. * healthy as confirmed by medical history, physical examinations, and the study doctor. * capable of signing informed consent. Participants will receive either: * the pdmFlu vaccine, * a licensed influenza vaccine * a placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will not know which vaccine they receive. Participants will receive the study vaccines as a single shot in the arm. The study will compare participant experiences to help understand if the pdmFlu vaccine is safe and effective. Participants will take part in this study for up to 13 months. During this time, the participants will receive the study vaccine and take part in follow-up visits.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL pdmFlu vaccine
- BIOLOGICAL Licensed influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2025-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06179446
The ClinicalTrials.gov registry entry for NCT06179446 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06179446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06179446 about?
NCT06179446 is a clinical study titled "A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza". The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Infl...
What is the current status of trial NCT06179446?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 157 participants. The study started on 2023-12-13. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT06179446?
The interventions under investigation include: Placebo (BIOLOGICAL), pdmFlu vaccine (BIOLOGICAL), Licensed influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06179446?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.